Kadriu, Bashkim
Farmer, Cristan A.
Yuan, Peixiong
Park, Lawrence T. http://orcid.org/0000-0002-6570-686X
Deng, Zhi-De
Moaddel, Ruin
Henter, Ioline D.
Shovestul, Bridget
Ballard, Elizabeth D.
Kraus, Cristoph
Gold, Philip W.
Machado-Vieira, Rodrigo
Zarate, Carlos A. Jr.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIA-MH002857, ZIA-MH002857, ZIA-MH002857, ZIA-MH002857, ZIA-MH002857, ZIA-MH002857, ZIA-MH002857, ZIA-MH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 6 June 2019
Revised: 21 October 2019
Accepted: 30 October 2019
First Online: 15 November 2019
Compliance with ethical standards
:
: CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ and RM are listed as co-inventors on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as co-inventors on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders. They have assigned their patent rights to the US government but will share a percentage of any royalties that may be received by the government. The remaining authors declare that they have no conflict of interest.